Cargando…

Aβ(42)/Aβ(40) and Aβ(42)/Aβ(38) Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study

Gait disturbances are some of the earliest changes in dementia and their monitoring presents an opportunity for early diagnosis. The exact relationship between gait and well-established biomarkers of Alzheimer’s disease (AD) remains to be clarified. In this study we compared gait-related measures wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koychev, Ivan, Galna, Brook, Zetterberg, Henrik, Lawson, Jennifer, Zamboni, Giovanna, Ridha, Basil H., Rowe, James B., Thomas, Alan, Howard, Robert, Malhotra, Paresh, Ritchie, Craig, Lovestone, Simon, Rochester, Lynn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218125/ https://www.ncbi.nlm.nih.gov/pubmed/30198873 http://dx.doi.org/10.3233/JAD-180622

Ejemplares similares

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers
por: Koychev, Ivan, et al.
Publicado: (2017)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Ageing Increases Vulnerability to Aβ42 Toxicity in Drosophila
por: Rogers, Iain, et al.
Publicado: (2012)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Nonphosphorylated tau slows down Aβ(1–42) aggregation, binds to Aβ(1–42) oligomers, and reduces Aβ(1–42) toxicity
por: Beeg, Marten, et al.
Publicado: (2021)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
por: Wang, Li, et al.
Publicado: (2021)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Low Cerebrospinal Fluid Aβ(42) and Aβ(40) are Related to White Matter Lesions in Cognitively Normal Elderly
por: Skoog, Ingmar, et al.
Publicado: (2018)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Impact of Aβ40 and Aβ42 Fibrils on the Transcriptome of Primary Astrocytes and Microglia
por: Zhu, Xiaoyue, et al.
Publicado: (2022)

Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42
por: Song, Chuli, et al.
Publicado: (2022)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Self-Assembly of Aβ40, Aβ42 and Aβ43 Peptides in Aqueous Mixtures of Fluorinated Alcohols
por: Pachahara, Sanjai Kumar, et al.
Publicado: (2015)

Dynamic Blood Concentrations of Aβ(1–40) and Aβ(1–42) in Alzheimer’s Disease
por: Yang, Yuan-Han, et al.
Publicado: (2020)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Short Aβ peptides attenuate Aβ42 toxicity in vivo
por: Moore, Brenda D., et al.
Publicado: (2018)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe
por: Yang, Jing, et al.
Publicado: (2020)

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression
por: Quartey, Maa O., et al.
Publicado: (2021)

Enhanced Aβ(1–40) Production in Endothelial Cells Stimulated with Fibrillar Aβ(1–42)
por: Rajadas, Jayakumar, et al.
Publicado: (2013)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

Varied Probability of Staying Collapsed/Extended at the Conformational Equilibrium of Monomeric Aβ(40) and Aβ(42)
por: Song, Wanling, et al.
Publicado: (2015)

The Position of Aβ(22−40) and Aβ(1−42) in Anionic Lipid Membranes Containing Cholesterol
por: Barrett, Matthew A., et al.
Publicado: (2015)

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ(40) and Aβ(42) Peptides in Plasma
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2016)

X-ray diffraction and electron microscopy data for amyloid formation of Aβ40 and Aβ42
por: Selivanova, Olga M., et al.
Publicado: (2016)

Presenilin 1 deficiency impairs Aβ42-to-Aβ40- and angiotensin-converting activities of ACE
por: Gao, Yuan, et al.
Publicado: (2023)

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways
por: Dammers, C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oi85u7oia6mh8ll79ui2fu6hk1